ETNB 8.24 89bio, Inc.
| Range: | 6.575-16.63 | Vol Avg: | 612218 | Last Div: | 0 | Changes: | 0.35 |
| Beta: | 0.99 | Cap: | 0.83B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Nov 11 2019 | Empoloyees: | 70 | ||
| CUSIP: | 282559103 | CIK: | 0001785173 | ISIN: | US2825591033 | Country: | US |
| CEO: | Mr. Rohan Palekar | Website: | https://www.89bio.com | ||||
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Stock Details
ETNB 12
89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
Brian Abrahams·Tue Aug 06 2024
RBC Capital
ETNB 25
UBS Reiterates Buy Rating on 89bio Inc. (ETNB)
Eliana Merle·Fri Jun 07 2024
UBS
ETNB 29
89bio Inc. (ETNB) PT Lowered to $29 at H.C. Wainwright
Ed Arce·Fri May 10 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow